Askgene Pharma, Inc.
Clinical trials sponsored by Askgene Pharma, Inc., explained in plain language.
-
New eye injection enters first human safety trial for Diabetes-Related vision loss
Disease control OngoingThis early-stage study is testing the safety and effects of a new drug called ASKG712, given as an injection into the eye, for people with diabetic macular edema (DME). DME is a swelling in the back of the eye that can cause vision loss in people with diabetes. The main goal is t…
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New eye injection enters human testing to fight leading cause of blindness
Disease control OngoingThis is the first study in people testing a new drug called ASKG712, given as an injection into the eye, for wet age-related macular degeneration (AMD). The main goal is to find out if different doses are safe and how the body processes the drug. Researchers will also check if th…
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Breakthrough combo targets aggressive stomach cancers
Disease control OngoingThis large Phase 3 trial is testing whether adding an experimental drug called ASKB589 to standard chemotherapy and immunotherapy works better for people with advanced stomach or gastroesophageal cancer. The study involves 780 patients in China who have a specific biomarker calle…
Phase: PHASE3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo tested in fight against advanced stomach cancer
Disease control OngoingThis study is testing a new drug called ASKB589, given alongside standard chemotherapy and immunotherapy, for people with advanced stomach or gastroesophageal junction cancer. The main goals are to find a safe dose and see how well the body handles the drug combination. Researche…
Phase: PHASE1, PHASE2 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC